Investor Presentation. February 2015

(1)

Investor Presentation

February 2015

(2)

FORWARD LOOKING STATEMENTS

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding Amyris’s product pipeline, sizes of markets that may be addressed by Amyris’s current and potential products, Amyris’s expected product pipeline, expected cash inflows from collaborations and product sales, product revenue pipeline and potential size, financial trends and outlook, operation of production facilities, commercial relationships, and Amyris’s projected financial results, including cash inflows, operating expenses, earnings and cash payback from a manufacturing plant, that involve risks and uncertainties. These statements and other forward-looking statements that may be provided in the presentation and/or oral statements accompanying it are based on management’s estimates and current expectations and actual results and future events may differ materially due to changes in Amyris’s business and various risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 7, 2014. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

NON-GAAP MEASURES

This presentation and oral statements accompanying this presentation contains both GAAP and non-GAAP financial information, because the

Company considers non-GAAP information to be a helpful measure to assess its operational performance and for financial and operational decision-making. The Company's non-GAAP financial information excludes stock-based compensation, loss on purchase commitments and write off of production assets, depreciation and amortization, gains and losses from changes in fair value of derivatives and debt extinguishment, but adds back accounts receivable, deferred revenue and funding associated with collaborations. A reconciliation of the non-GAAP financial measures presented in this presentation to their GAAP equivalents, is provided in the Company’s Q3 2014 earnings press release dated November 7, 2014.

Additionally, please note during this presentation, we may discuss historical non-GAAP financial measures. For each non-GAAP financial measure discussed a presentation of the most directly comparable GAAP financial measure and a reconciliation of the difference between the non-GAAP financial measure discussed and the most directly comparable GAAP measure is available in the Investor Relations section of the Company’s

(3)

The Industrial Bioscience Company

COMPANY HIGHLIGHTS

• Founded in 2003 by post-doctoral fellows

from the University of California, Berkeley

• Headquartered in the San Francisco Bay

Area and with operations in Brazil

• 395 full-time employees (27% of US

employees are PhDs)

• Over 135 issued patents and nearly 300

pending applications



Proven technology, multiple molecules



Operating at industrial manufacturing scale



Differentiated & proven business model

AMYRIS BIOREFINERY IN BRAZIL

BIOLDING

investment

LEADING INVESTORS

KEY FINANCIAL OUTLOOK

Renewable Products CAGR 100% Y-o-Y

Cash Gross Margin Range 50-60%

Molecules in Pipeline Over 20

(4)

2012

2014

2011

2010

2013

Launched IPO and listed on NASDAQ

Amyris sells diesel in a bus fleet - Brazil Diesel de Cana TM

First renewable jet fuel demo flight

First commercial shipment from Brotas

Advanced innovative collaboration to develop ingredients for F&F markets

Expanded Firmenich collaboration Expanded partnership products VW partners with Amyris to promote automotive uses of renewable fuels Amyris-Total demo flight in Airbus 321 (Paris Air Show)

Continued to expand squalane sales Signed collaboration

agreement with Total

Signed F&F

collaboration with IFF

Formed fuels joint venture with Total

Expanded collaboration in farnesene-based polymers

Added multiple new collaborations Signed collaboration

agreements with

Signed collaboration agreement with Firmenich for F&F

Awarded $8MM DARPA contract

Further expanded Firmenich collaboration

Sanofi begins production of anti-malarial drug

Amyris-Total renewable jet fuel begins commercialization Secured downstream processing facility in the U.S.

Key Milestones

(5)

(6)

Build Strains Test Strains and Processes 120,000 strains per month 60 strains per month 2 strains per month 2 to 4 strains per year Manufacture Millions strains per month 96-well Screening Mutagenesis, Meiosis & Automated Strain Engineering 0.5 & 2 Liter Fermentation 300 Liter Fermentation & Recovery 200,000 Liter Fermentation & Recovery

Price & Supply

Volatility

Consumer

Demand for

Naturals

Need for Higher

Performance at

Competitive Price

LEADING COLLABORATION PARTNERS

Target Market

Characteristics

• Emollients • Fragrances Consumer Care • Theraupeutic and Drug Discovery Biopharma • Polymers • Solvents and Fluids Perf. Materials • Diesel • Jet Fuel Fuels • Base Oils • Finished Lubricants Lubricants

Proven Technology Platform

(7)

Industrialization of Synthetic Biology

Scale-down, standardize, & automate

• 1000X capacity gain

• Economies of scale

• Automated data acquisition

Total Quality Management

• Continuous improvement

• Perfect reproducibility

• Only ask each question once

Traditional Biotechnology

Industrialized Synthetic Biology

“Artisan” approach to biology

• Limited capacity

• Limited data acquisition

(8)

Farnesene

First Generation

Farnesene

Second Generation

Fragrance 1

Fragrance 2

Fragrance 3

Ef

fic

ien

c

y

(Y

ie

ld)

(9)

Lab

2 L

Pilot Plant

300 L

Pilot Plant

300 L

Demo Plant

5,000 L

Production

6 x 200,000 L

Lab

2 L scale

PRODUCTION COST EVOLUTION

($/L, non-GAAP)

0

10

20

30

40

50 Integrated Manufacturing

$3/L Today

(10)

(11)

e n g i n e t r a n s f o r m e r h y d r a u l i c d i e s e l j e t AROMAS COSMETICS f r a g r a n c e o i l s p o l y m e r s s o l v e n t s a d h e s i v e s & c o a t i n g s s q u a l a n e h e m i s q u a l a n e L U B R I C A N T S R E N E W A B L E MO B I L I T Y C O N S U ME R C A R E P E R F O R MA N C E MA T E R I A L S

(12)

$4B

$9B

$18B

$40B

$123B

$212B

$1.6T

Emollients, Moisturizers, Film Formers

F&F Ingredients Elastomers and Synthetic Rubbers &

Plastic Additives

Auto & Industrial Lubricants

Bulk Polymers, Coatings, Adhesives

and Polyolefins

Jet Fuel Diesel Fuel

Over $100 Billion Addressable Market

at Current Commercial Performance

Over $1 Trillion Total Addressable

Market Ahead

(13)

COLLABORATIONS

RENEWABLE PRODUCTS

COLLABORATION INFLOWS

$60M to $70M Annual

PRODUCTION & SALES

2X Annual Growth

FUNDS THE BUSINESS

Over 20 new

molecules under

contract with 1 to

3 new product

launch per year

PROVIDES REVENUE GROWTH AND

EARNINGS UPSIDE

More than 20 molecules under

contract 1-to-3 new product

launches/year

(14)

Opportunity

(

Assessment)

 Pharma  Nutraceuticals  Agroscience  Flavors, Cosmetics, Polymers

Co-Engineering

(Feasibility)

 Multiple Fragrances  Vitamins

Current Engineering

(Development)

 Solid Farnesene Rubber*, Elastomers (e.g. sealants, adhesives)  Fragrance Ingredients  3 from Farnesene

 3 from New Strains*

*Development in partnership

2014 First Sales

(Launch)

 Liquid Farnesene Rubber*  Cleaning Solvent  Hemisqualane  Jet Fuel

Commercial Business

(Ongoing Revenue)

 Diesel  Squalane  Fragrance Oil #1

(15)

Collaboration-to-Products in Practice

$0

$10

$20

$30

$40

$50

$60

$70

$80

$90

Fragrance #1

Collaboration Funding Inflow

C

ol

lab

o

ra

ti

on

I

n

fl

o

w

s

an

d P

ro

d

uc

t

R

ev

e

nu

e

(

N

on

-GAAP)

$M

2010

2014

2018

Fragrance #2 Fragrance #3

(16)

(17)

$21 $41 $66 $61 $48 $133 $91 $88 $37 $5 $43 $28 $69 $100 $200 $300 $400 $500 $600 $700 $800

Series A Series B Series B-1

Series C Series C-1

Series D IPO 2010 Feb 2012 Winter 2012 Spring 2013 Fall 2013 Winter 2013 Spring 2014 M illio n s

(18)

78.8 72.0 91.3 31.9 30.0 _TOTAL Convertibles Temasek Convertibles Institutional Holders of Convertibles Development Banks & Project

Financing Hercules Term Loan 0.2 2.2 30.0 78.4 6.1 54.6 34.0 2.2 75.0 23.6 306.3 50.0 100.0 150.0 200.0 250.0 300.0 350.0

Nov'14 Mar'15 Feb'17 Mar'17 Dec'17 Oct'18 Jan'19 Apr'19 May'19 Jul'22 Total

Current Debt Breakdown by Maturity

($ in millions, as of June 2014)

Leading Equity Holders

$306.3M Debt Breakdown by Holder

($ in millions, as of June 2014)

$53.4 Converts TOTAL R&D $25.0 Converts Fidelity

Capital Structure

(19)

Geoff Duyk

John Melo

Patrick Yang

Philippe Boisseau

Carole Piwnica

B I O L D I N G I N V E S T M E N T S

HH Sheikh Abdullah

bin Khalifa Al Thani

Neil Williams

Fernando Reinach

Nam-Hai Chua*

John Doerr

(20)